用於精神疾病的新診斷技術

用於精神疾病的新診斷技術 是由出版商Decision Resources, Inc.在2008年05月所出版的。 這份英文市場調查報告書包含38 Pages 價格從美金2250起跳。

簡介

目錄

Abstract

Introduction

The diagnosis of psychiatric diseases is an inexact science and a slow process for physicians. No laboratory tests are available to determine the exact disease-or treatment. New diagnostic technologies could offer earlier, more specifi c diagnosis of a psychiatric disease and even direct potential drug therapy. In this report, we discuss the treatment challenges that confront physicians and patients and review current and emerging diagnostic tests that are expected to change the way in which psychiatric diseases are diagnosed. This report also features three Expert Commentaries, two offering input from the diagnostic technology industry, and one highlighting Decision Resources' primary research with physicians who discuss their views of biomarkerbased diagnostic tests for psychiatry.

Get the Answers You Need to Shape Your Strategy

• The diagnosis of mental illness is far from an exact science, with no laboratory tests to confi rm a disorder or offer treatment strategies. What technologies are emerging that will expedite diagnosis and treatment of psychiatric disorders? How will these technologies affect R&D within the pharmaceutical industry?
• EEG, molecular, genetic, and imaging diagnostics are all poised for use in the fi eld of psychiatry. How will the technologies that exist to aid diagnosis expand into the fi eld of mental health? What companies already have clinical trials under way and what diagnostic tools are they using? How will these studies target patient response to some of today' s most popular psychiatric drugs? What challenges do manufacturers face when developing these diagnostics?
• Expert Commentaries: two company executives and one market analyst discuss the impact of novel diagnostics in the psychiatric arena. What are thought leaders saying about the potential for biomarkers in mental health diagnosis and treatment? How will a new EEG tool help psychiatrists target drug therapy in their patients? How can gene-expression profi les lead to differential diagnoses or offer insight into disease-specifi c subtyping?

Scope

• Diffi culties diagnosing mental illness: addressing similar symptomatology; multiple mental illnesses in one patient; challenges in determining optimal treatment; current medical practice for psychiatric indications.
• Current and emerging diagnostic technologies for psychiatric indications: EEG (Aspect Medical Systems, CNS Response, Memory Pharmaceuticals/Roche); molecular diagnostics (Clinical Data, CombiMatrix, Curidium Medica, Roche/Affymetrix, Vanda Pharmaceuticals); diagnostic imaging (Alseres).
• Psychiatric disorders: attention-defi cit/hyperactivity disorder; autism spectrum disorder; bipolar disorder; major depression; schizophrenia; psychotic disorders.
• Business considerations: review of partnerships and licensing activities; benefi ts of drug/theranostic codevelopment; challenges and opportunities.

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• The Importance of Diagnostic Technologies for Psychiatric Indications
• Value of Biomarker-Based Diagnostics for Psychiatric Diseases
• Diffi culties in Diagnosing Psychiatric Illness
  • Presentation of Prodromal Symptoms Can Be Slow and Variable
  • Several Disorders May Have Similar Symptomatology
  • Patients with Multiple Mental Illnesses May be Diffi cult to Diagnose
  • Some Mental Illnesses May Be Broad Categories of Diseases
• Challenges in Determining Optimal Treatment
• Current Medical Practice for Psychiatric Indications
• Current and Emerging Diagnostic Technologies for Psychiatric Indications
  • Electroencephalography
    • Aspect Medical Systems
    • CNS Response
    • Memory Pharmaceuticals/Roche and Envivo Pharmaceuticals
  • Molecular Diagnostics
    • Clinical Data
    • CombiMatrix
    • Curidium Medica
    • Roche/Affymetrix
    • Vanda Pharmaceuticals
  • Diagnostic Imaging
• Outlook
• Appendix A. Thought Leaders Consulted for This Report
• Appendix B. Bibliography

Expert Commentaries

• What Do Thought Leaders Say About the Potential Use of Biomarkers in Psychiatric Diagnosis and Treatment?
  • Carlos Dedesma, Analyst, Decision Resources, Inc
• The Potential for rEEG to Create Win-Win Situations for Stakeholders
  • Leonard Brandt, CEO, CNS Response
• Disentangling Patient Populations to Develop More-Effective Drug Therapies
  • Anne T. Bruinvels, Ph.D., Founder and CSO, Curidium Medica

Sidebar

• 510(k) vs. PMA

Tables

• 1. Diagnostic Collaborations in Psychiatric Indications, 2004-March 2008
• 2. Roche' s AmpliChip CYP450 Test: Summary of Attributes
• 3. Major Opportunities and Challenges for Psychiatric Diagnostics

• A. Drug Development Benefi ts by Development Phase

Figures

• 1. How Diagnostic Technologies Can Increase Treatment Effi cacy
• 2. Referenced-EEG Sample Report to Physicians from CNS Response

• A. Medications Predicted by rEEG
• B. Schematic Overview of the Studies Undertaken by Curidium to Identify a Blood Diagnostic Tool to Select Schizophrenia and Bipolar Disorder Patient Subgroups in the Clinic

相關商品

精神病相關市場調查報告書

抗精神病藥物市場(∼2017年):金普薩(Zyprexa)·安立復(Abilify)·思樂康(Seroquel)·哲思(Geodon)專利到期，及學名藥開始販售將限制開發平台分子商業機會的可能性
Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules
價格 : US $ 3500
出版日期 : 2012年01月

阿茲海默症：新藥・市場・企業
Alzheimer disease - new drugs, markets and companies
價格 : US $ 3500
出版日期 : 2012年01月

憂鬱症:針對二線患者的新一代產品競爭
Product Profiles: Depression - Next generation vies for second-line patients
價格 : US $ 11400
出版日期 : 2011年11月

Decision Resources, Inc.發行的製藥相關市場調查報告書

傳染病疫苗開發平台:競爭檢討

Special Report: The Infectious Disease Vaccine Pipeline--A Competitive Review

價格 : US $ 9200

出版日期 : 2011年06月

感染疾病疫苗:未滿足需求和對醫藥品產業來說的機會

Special Report: Infectious Disease Vaccines--Unmet Needs and Opportunities for Pharma

價格 : US $ 9200

出版日期 : 2011年06月

自閉症譜系障礙:高未滿足需求創造出很大的市場機會

Special Report: Autism Spectrum Disorders--High Unmet Needs Create Significant Market Opportunities

價格 : US $ 9200

出版日期 : 2011年06月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!